menu
    • menu
    [{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Povorcitinib","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Povorcitinib","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"China Medical System Holdings Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Povorcitinib","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ China Medical System Holdings Limited","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ China Medical System Holdings Limited"}]

    Find Clinical Drug Pipeline Developments & Deals for Povorcitinib

    Menu

    Povorcitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Incyte Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Incyte Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Povorcitinib

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : China Medical System Holdings Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Incyte and Cms Announce Collaboration and License Agreement for Povorcitinib

                            Details : CMS will be responsible for developing and commercializing INCB54707, it is being evaluated for non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma.

                            Brand Name : INCB054707

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 01, 2024

                            Lead Product(s) : Povorcitinib

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : China Medical System Holdings Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Incyte Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Incyte Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Povorcitinib

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Incyte Presents New Late-Breaking Data from Phase 2 Evaluating Povorcitinib

                            Details : INCB54707 (povorcitinib) is an oral small-molecule JAK1 inhibitor currently in Phase 2 clinical trial for adult patients with prurigo nodularis. A Phase 3 trial is being planned for prurigo nodularis.

                            Brand Name : INCB054707

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 10, 2024

                            Lead Product(s) : Povorcitinib

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Incyte Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Incyte Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Povorcitinib

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidra...

                            Details : INCB54707 (povorcitinib) is an oral small-molecule JAK1 inhibitor currently in Phase 2 clinical trials for hidradenitis suppurativa (HS), vitiligo and prurigo nodularis. A Phase 3 study in HS is also ongoing.

                            Brand Name : INCB054707

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 10, 2023

                            Lead Product(s) : Povorcitinib

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Incyte Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Incyte Corporation

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Povorcitinib

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatolo...

                            Details : Povorcitinib (INCB054707) is an oral small-molecule JAK1 inhibitor currently in Phase 2 clinical trials for hidradenitis suppurativa (HS), vitiligo and prurigo nodularis.

                            Brand Name : INCB054707

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 24, 2022

                            Lead Product(s) : Povorcitinib

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth